Clinical Trials Logo
  1. Home
  2. Lymphoid Leukemia
  3. NCT00801580

My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia

Lymphoid Leukemia Clinical Trial

Official title:
Open Label, Non-randomized, Phase II Study on Fractioned Cyclophosphamide, Vincristine, Liposomal Doxorubicin or Doxorubicin, and Dexamethasone (MY HYPER-CVAD) in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia

Clinical Trial Summary

The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00801580
Study type Interventional
Source University of Bologna
Contact Giovanni Martinelli, MD
Phone +39 051 6363829
Email gmartino@alma.unibo.it
Status Recruiting
Phase Phase 2
Start date March 2008
Completion date September 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00469729 - Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Phase 2/Phase 3
Completed NCT03575325 - Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Phase 2
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Completed NCT02593123 - Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis Phase 2
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Completed NCT01754857 - Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Phase 2
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Terminated NCT01643603 - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Completed NCT02719821 - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT05871008 - Integrated Actionable Aging Assessment for Cancer Patients Pilot N/A
Terminated NCT04155840 - Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Suspended NCT02462265 - Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients Phase 2
Completed NCT02955043 - Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery N/A
Not yet recruiting NCT05865301 - Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Recruiting NCT05507827 - Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) Phase 1